Malaria
Conditions
Keywords
Randomized, Assays, Blood Smear, Antibody, Parasites
Brief summary
Background: Malaria affects many people in Mali and other parts of Africa. It is spread by mosquito bites. Malaria can make people sick or can lead to death. Scientists want to learn if a vaccine can stop it from spreading to other people. Objective: To test how well an experimental malaria vaccine works to decrease malaria infections. Eligibility: Healthy people ages 5 and older who live in Doneguebougou, Mali, and surrounding areas Design: Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests EKG Participants will be randomly assigned to get either the experimental vaccine or an approved vaccine. They will not know which they are getting. Participants will have a visit about a week before their first vaccine. They will take a medicine that kills malaria. They will take it at the clinic the next 2 days. Participants ages 5-8 will take the drug again 2 weeks before their third vaccine. Participants get the vaccine through a needle in the arm. They will have visits 1, 3, 7, and 14 days after. They will have blood tests or finger pricks. Participants will get another vaccine 1 and 6 months later. Participants will have blood tests once a month. At these visits they may also have urines tests or mosquito feeds. For the feeds a cup full of mosquitoes will be placed on arms or legs for 15-20 minutes. Participants will have visits twice a month for 4 months after their last vaccine.
Detailed description
A vaccine to interrupt malaria transmission (VIMT), targeting disruption of both human and mosquito transmission, would be a valuable tool for local elimination or eradication of this disease. One strategy to design a VIMT is using components that block transmission of malaria to mosquitoes, such as Pfs230. Pfs230, a surface antigen of intracellular gametocytes, as well as extracellular gametes and zygotes in the mosquito stage of Plasmodium falciparum, is currently the leading candidate in clinical trials for a malaria transmission-blocking vaccine (TBV). Recombinant Pfs230D1M has been conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA) and adjuvanted with AS01. When formulated in AS01, results from a recent first-in-human trial demonstrated that Pfs230-EPA induces functional transmission-reducing, and in a significant proportion of vaccinees, transmission-blocking serum activity that can be measured for months, the vaccine is well-tolerated and safe in adults, and our recent natural history data clearly indicate that children play a disproportionate role in malaria transmission. The next step in the development of Pfs230D1M-EPA as a TBV is therefore to conduct an age de-escalation trial to ensure that the vaccine is safe to administer to children and then to conduct a community clinical trial to assess efficacy in family groups. This Phase 2 study will first determine safety and tolerability of Pfs230D1M-EPA/AS01 in healthy Malian children of decreasing ages: 9-18 years old, followed by 5-8 years old. A total of 60 subjects will be enrolled in Doneguebougou, Mali, West Africa. Children will be recruited from compounds/family that have agreed to participate in the main phase of the study and will enroll in a staggered manner to receive either Pfs230D1M-EPA/AS01 vaccine or comparator as assigned by their compound block randomization. Prior to receipt of vaccination #1, all subjects will receive a full treatment course of artemether/lumefantrine (AL). Safety and tolerability will be monitored and reported as local and systemic adverse events (AEs) and serious adverse events (SAEs) and reviewed by DSMB, sponsor, medical monitors, and study team prior to proceeding with enrollment of the main phase. If there are no safety concerns, in a staggered manner, the main phase will begin enrollment of approximately 137 compounds/vaccine units (about 1500 vaccinees + about 400 under 5 years of age for parasite surveillance). Children enrolled during the pilot safety phase will join their main phase compounds/family for vaccination #3. Prior to receipt of first vaccination, all subjects will receive a full treatment course of AL. All vaccinated subjects will be monitored for safety and tolerability. Immunogenicity outcomes will be antibody responses as measured by enzyme-linked immunosorbent assay (ELISA) against recombinant Pfs230D1M. Functional activity of the induced antibodies will be assessed by standard membrane feeding assays in select samples. Vaccine activity will be measured in children 9-18 years of age who will undergo direct skin feeds (DSF) starting 2 weeks post vaccination #3 for a total of 8 DSFs. Prior to scheduled last vaccination in members of the compound/family, children 1-4 years of age and vaccinated children 5-8 years of age will receive a full treatment course of AL prior to the expected start of the transmission season and will then be followed every 2 weeks by blood smear (BS) along with all vaccinated children. Children 9-18 years of age will also be assessed for vaccine efficacy, but as a separate analysis from those 1-8 years of age. In Year 2, those who received vaccination during Year 1 (5 years of age and older at enrollment), if eligible and still on study, will receive a single fourth vaccination per their vaccine unit (VU) blinded arm assignment. No new individuals will be enrolled. Again, children 1-4 years of age and vaccinated children 5-8 years of age will receive a full treatment course of AL prior to the expected start of the transmission season and will then be followed every 2 weeks by BS along with all vaccinated children. Children 9-18 years of age will also be assessed for vaccine efficacy against parasitemia, but as a separate analysis from those 1-8 years of age. Immunogenicity outcomes will be antibody responses as measured by ELISA against recombinant Pfs230D1M. Functional activity of the induced antibodies will be assessed by standard membrane feeding assays in select samples. Vaccine activity will be measured in children 9-18 years of age who will undergo DSF starting 2 weeks post vaccination #4 for a total of 10 DSFs.
Interventions
BIOLOGICALPfs230D1M-EPA/AS01
The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
BIOLOGICALHAVRIX
HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
BIOLOGICALTYPHIM Vi (Salmonella typhi vaccine)
TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
BIOLOGICALMenactra
Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
BIOLOGICALAVAXIM
AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA FOR GROUPS 1,2,3: All of the following criteria must be fulfilled for a volunteer to participate in this trial: 1. Meets age requirements for Arm currently being enrolled. 2. Available for the duration of the trial. 3. Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages. 4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 5. In good general health and without clinically significant medical history in the opinion of the investigator. 6. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 0 and until 1 month after the last vaccination. * A reliable method of birth control includes one of the following: <!-- --> 1. Confirmed pharmacologic contraceptives (parenteral) delivery; 2. Intrauterine or implantable device EXCEPTIONS to required pregnancy prevention includes the following: 1. Postmenopausal state: defined as no menses for 12 months without an alternative medical cause 2. Surgical sterilization 3. Unmarried AND not sexually active AND menstruating OR not menstruating females 12-17 years of age 4. NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become \>=18 years of age, married, or sexually active), the female will be required to start reliable contraception 7\. Willing to have blood samples stored for future research. INCLUSION CRITERIA FOR GROUP 4: All of the following criteria must be fulfilled for a volunteer to participate in this trial: 1. Meets age requirements for Arm currently being enrolled. 2. Available for the duration of the trial. 3. Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages. 4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 5. In good general health and without clinically significant medical history in the opinion of the investigator. 6. Willing to have blood samples stored for future research. Inclusion Criteria for Groups 1, 2, 3, (Year 2) All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial: 1\. Previously enrolled in the study and has received at least 1 vaccination. 2. Available for the duration of the trial. 3\. In good general health and without clinically significant medical history in the opinion of the investigator. 4\. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to scheduled vaccine dose #4 and until 1 month after the 4th vaccination. -A reliable method of birth control includes one of the following: 1. Confirmed pharmacologic contraceptives (parenteral) delivery; 2. Intrauterine or implantable device EXCEPTIONS to required pregnancy prevention includes the following: 1. Postmenopausal state: defined as no menses for 12 months without an alternative medical cause 2. Surgical sterilization 3. Unmarried AND not sexually active AND menstruatingOR not menstruating females 12-17 years of age 4. NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become greater than or equal to 18 years of age, married, or sexually active), the female will be required to start reliable contraception 5. Willing to have blood samples stored for future research. Inclusion Criteria for Group 4 (Year 2): All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial: 1. Previously enrolled in the study 2. Available for the duration of the trial. 3. In good general health and without clinically significant medical history in the opinion of the investigator. 4. Willing to have blood samples stored for future research.
Exclusion criteria
FOR GROUPS 1, 2, 3: An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled: 1. Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing 2. Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.) 3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age. 4. Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and \<= Grade 2.) 5. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and \<= Grade 2.) 6. Infected with HIV 7. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis. 8. Clinically significant prolonged QTc (\>450 milliseconds) on screening EKG 9. History of receiving any investigational product within the past 30 days. 10. Current or planned participation in an investigational vaccine study until the last required protocol visit. 11. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. 12. History of a severe allergic reaction or anaphylaxis. 13. Known: * Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years. * Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sj(SqrRoot)(Delta)gren s syndrome, or autoimmune thrombocytopenia. * Immunodeficiency syndrome. * Seizure disorder (exception: history of simple febrile seizures) * Asplenia or functional asplenia. * Use of chronic (\>=14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0. * Allergy to latex or neomycin * Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past * Adverse reaction to artemether/lumefantrine in the past 14. Receipt of: -Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment. * Immunoglobulins and/or blood products within the past 6 months. * Investigational malaria vaccine in the last 2 years. 15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol. Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the PI. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | Within 7 days after each vaccination at days, 0, 28, 126, 448 (for arms 1a, 1b, 2a, 2b), days 0, 28, 56, 392 (for arms 3a, 3b, 3c, 3d, 3e, 3f), days -14 and 385 (for arms 4a, 4b) and year 2 (for all arms) | Number of participants with local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine |
Countries
Mali
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm 1a Pilot/safety: Dosing interval on days: 0, 28, 126, 448
Participants received 4 doses of 40 μg of Pfs230D1M-EPA/AS01 administered via intramuscular (IM) injection on days: 0, 28, 126, 448; receipt of artemether/lumefantrine (AL) on day -7 | 15 |
| Arm 1b Pilot/safety: Dosing interval on days: 0, 28, 126, 448
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 28 to receove TYPHIM Vi; and day 126 to receive Menactra; receipt of AL on day -7 | 15 |
| Arm 2a Pilot/safety: Dosing interval on days: 0, 28, 126, 448
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 126, 448 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7,112, 441 | 15 |
| Arm 2b Pilot/safety: Dosing interval on days: 0, 28, 126, 448
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 448 to receive HAVRIX; day 126 to receive Menactra; receipt of AL on day -7,112, 441 | 15 |
| Arm 3a Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7, 42, 385 | 99 |
| Arm 3b Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7, 42, 385 | 87 |
| Arm 3c Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | 192 |
| Arm 3d Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | 177 |
| Arm 3e Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 28, 56, 392 to receive 40 μg of Pfs230D1M-EPA/AS01; receipt of AL on day -7 | 227 |
| Arm 3f Safety/efficacy: Dosing interval on days 0, 28, 56, 392
Participants received 4 doses administered via intramuscular (IM) injection on days 0, 392 to receive HAVRIX; day 28 TYPHIM Vi; day 56 to receive Menactra; receipt of AL on day -7 | 267 |
| Arm 4a AL treatment only; no vaccination
Participants received AL on day -14, 385 | 97 |
| Arm 4b AL treatment only; no vaccination
Participants received AL on day -14, 385 | 95 |
| Total | 1,301 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year 1 | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Year 1 | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Year 1 | Missed visits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Year 1 | Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Year 1 | Spouse/Family member request | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| Year 1 | Subject moved away from site | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 3 |
| Year 1 | Travel | 0 | 1 | 1 | 0 | 4 | 4 | 10 | 8 | 2 | 5 | 3 | 3 |
| Year 1 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 1 | 6 | 2 | 5 | 3 | 1 | 0 |
| Year 2 | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Year 2 | Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Year 2 | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| Year 2 | Married | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Year 2 | Spouse/family member request | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Year 2 | Subject moved away from site | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 0 | 2 | 0 | 1 |
| Year 2 | Travel | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 1 |
| Year 2 | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 5 | 0 | 0 |
| Year 2 | Year 2 Screening failure | 0 | 1 | 0 | 0 | 2 | 0 | 4 | 3 | 10 | 2 | 1 | 1 |
Baseline characteristics
| Characteristic | Arm 1b | Total | Arm 4b | Arm 4a | Arm 3f | Arm 3e | Arm 3d | Arm 1a | Arm 3c | Arm 3b | Arm 3a | Arm 2b | Arm 2a |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 15 Participants | 783 Participants | 95 Participants | 97 Participants | 0 Participants | 0 Participants | 167 Participants | 15 Participants | 178 Participants | 87 Participants | 99 Participants | 15 Participants | 15 Participants |
| Age, Categorical >=65 years | 0 Participants | 37 Participants | 0 Participants | 0 Participants | 18 Participants | 19 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 481 Participants | 0 Participants | 0 Participants | 249 Participants | 208 Participants | 10 Participants | 0 Participants | 14 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Bambara | 11 Participants | 575 Participants | 32 Participants | 41 Participants | 139 Participants | 115 Participants | 51 Participants | 9 Participants | 84 Participants | 34 Participants | 51 Participants | 2 Participants | 6 Participants |
| Race/Ethnicity, Customized Bozo | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Malinke | 0 Participants | 15 Participants | 0 Participants | 5 Participants | 0 Participants | 6 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 10 Participants | 2 Participants | 0 Participants | 2 Participants | 0 Participants | 4 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Peulh | 1 Participants | 38 Participants | 3 Participants | 5 Participants | 4 Participants | 8 Participants | 0 Participants | 0 Participants | 12 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Sarakole | 3 Participants | 661 Participants | 58 Participants | 45 Participants | 122 Participants | 98 Participants | 121 Participants | 6 Participants | 93 Participants | 51 Participants | 45 Participants | 11 Participants | 8 Participants |
| Race/Ethnicity, Customized Sonrhai | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Mali | 15 participants | 1301 participants | 95 participants | 97 participants | 267 participants | 227 participants | 177 participants | 15 participants | 192 participants | 87 participants | 99 participants | 15 participants | 15 participants |
| Sex: Female, Male Female | 8 Participants | 653 Participants | 43 Participants | 44 Participants | 147 Participants | 126 Participants | 91 Participants | 6 Participants | 84 Participants | 43 Participants | 50 Participants | 6 Participants | 5 Participants |
| Sex: Female, Male Male | 7 Participants | 648 Participants | 52 Participants | 53 Participants | 120 Participants | 101 Participants | 86 Participants | 9 Participants | 108 Participants | 44 Participants | 49 Participants | 9 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 99 | 1 / 87 | 0 / 192 | 0 / 177 | 2 / 227 | 5 / 267 | 0 / 97 | 0 / 95 |
| other Total, other adverse events | 15 / 15 | 14 / 15 | 15 / 15 | 15 / 15 | 95 / 99 | 84 / 87 | 187 / 192 | 170 / 177 | 222 / 227 | 253 / 267 | 89 / 97 | 84 / 95 |
| serious Total, serious adverse events | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 15 | 1 / 99 | 1 / 87 | 0 / 192 | 2 / 177 | 2 / 227 | 7 / 267 | 0 / 97 | 1 / 95 |
Outcome results
Primary
Number of Participants With Local and Systemic Adverse Events in Years 1 and 2
Number of participants with local and systemic adverse events (AEs) graded by severity occurring within 7 days after each vaccine
Time frame: Within 7 days after each vaccination at days, 0, 28, 126, 448 (for arms 1a, 1b, 2a, 2b), days 0, 28, 56, 392 (for arms 3a, 3b, 3c, 3d, 3e, 3f), days -14 and 385 (for arms 4a, 4b) and year 2 (for all arms)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm 1a | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 15 Participants |
| Arm 1b | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 14 Participants |
| Arm 2a | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 15 Participants |
| Arm 2b | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 15 Participants |
| Arm 3a | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 96 Participants |
| Arm 3b | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 85 Participants |
| Arm 3c | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 187 Participants |
| Arm 3d | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 172 Participants |
| Arm 3e | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 224 Participants |
| Arm 3f | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 260 Participants |
| Arm 4a | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 89 Participants |
| Arm 4b | Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 | 85 Participants |